Dynamic changes in gut microbiota under the influence of smoking and TNF-α-blocker in patients with ankylosing spondylitis

Zhang, Fangze; Ma, Cuili; Zhang, Bin; Bi, Liqi

doi:10.1007/s10067-020-05032-4

Cited by 22 publications

(14 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although not the main objective of the study, taxonomic profiling in this study failed to reveal differences in alpha or beta diversity by multiple measures (Supplemental Figures 4A-E) or in higher order OTUs between the axSpA and HC groups (Figures 2A, B). Such a result is likely due to the use of TNFi in our subjects, as TNFi has previously been shown to "normalize" the microbiome in axSpA (47)(48)(49). To further assess the role of specific bacterial differences across axSpA, a comparison was made across the most previously Figure 6) (4, 6, 7).…”

Section: Discussionmentioning

confidence: 94%

Multi ‘Omics Analysis of Intestinal Tissue in Ankylosing Spondylitis Identifies Alterations in the Tryptophan Metabolism Pathway

Berlinberg

Regner²,

Stahly

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

Intestinal microbial dysbiosis, intestinal inflammation, and Th17 immunity are all linked to the pathophysiology of spondyloarthritis (SpA); however, the mechanisms linking them remain unknown. One potential hypothesis suggests that the dysbiotic gut microbiome as a whole produces metabolites that influence human immune cells. To identify potential disease-relevant, microbiome-produced metabolites, we performed metabolomics screening and shotgun metagenomics on paired colon biopsies and fecal samples, respectively, from subjects with axial SpA (axSpA, N=21), Crohn’s disease (CD, N=27), and Crohn’s-axSpA overlap (CD-axSpA, N=12), as well as controls (HC, N=24). Using LC-MS based metabolomics of 4 non-inflamed pinch biopsies of the distal colon from subjects, we identified significant alterations in tryptophan pathway metabolites, including an expansion of indole-3-acetate (IAA) in axSpA and CD-axSpA compared to HC and CD and indole-3-acetaldehyde (I3Ald) in axSpA and CD-axSpA but not CD compared to HC, suggesting possible specificity to the development of axSpA. We then performed shotgun metagenomics of fecal samples to characterize gut microbial dysbiosis across these disease states. In spite of no significant differences in alpha-diversity among the 4 groups, our results confirmed differences in gene abundances of numerous enzymes involved in tryptophan metabolism. Specifically, gene abundance of indolepyruvate decarboxylase, which generates IAA and I3Ald, was significantly elevated in individuals with axSpA while gene abundances in HC demonstrated a propensity towards tryptophan synthesis. Such genetic changes were not observed in CD, again suggesting disease specificity for axSpA. Given the emerging role of tryptophan and its metabolites in immune function, altogether these data indicate that tryptophan metabolism into I3Ald and then IAA is one mechanism by which the gut microbiome potentially influences the development of axSpA.

show abstract

Section: Discussionmentioning

confidence: 94%

Multi ‘Omics Analysis of Intestinal Tissue in Ankylosing Spondylitis Identifies Alterations in the Tryptophan Metabolism Pathway

Berlinberg

Regner²,

Stahly

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Another cross-sectional study of the relationship between smoking status and microbiota also showed a difference in b diversity between never-smokers and current smokers (Lee et al, 2018). The b diversity in smokers with ankylosing spondylitis was lower than that in nonsmokers (Zhang et al, 2020). However, other studies did not find diversity differences between smokers and nonsmokers (Nolan-Kenney et al, 2020).…”

Section: Duration Of Breastfeeding Was Associated With the Relative Abundance Of Lactobacillus And Clostridium_sensu_stricto_1mentioning

confidence: 94%

Environmental Tobacco Smoke Exposure and Breastfeeding Duration Influence the Composition and Dynamics of Gut Microbiota in Young Children Aged 0–2 Years

Xie

Wang

Zou

et al. 2020

Biological Research For Nursing

View full text Add to dashboard Cite

The colonization characteristics of infant gut microbiota are influenced by many factors at various stages, but few studies have explored the longitudinal effects of environmental tobacco smoke exposure and quantitative breastfeeding duration on young children’ gut microbiota. We explored the effects of smoke exposure and breastfeeding duration on gut microbiota by following 37 maternal and children pairs in China for 2 years. We collected the demographic information, frequency of smoke exposure, breastfeeding duration, and fecal samples (mothers in the late pregnancy and infants at 6, 12, and 24 months), and analyzed the microbiota results using the V3-V4 gene sequence of 16S rRNA. The diversity of gut microbiota in children was the highest at 24 months and most similar to that in mothers. Breastfeeding duration was positively correlated with Lactobacillus and negatively correlated with Clostridium_sensu_stricto_1. The α diversity of microbiota and the relative abundance of [Ruminococcus]_gnavus_group was higher in the non-smoke exposed group. The higher the smoke exposure, the higher the relative abundance of Megasphaera. Prolonged breastfeeding and reduced smoke exposure are beneficial to the diversity and composition of gut microbiota in young children.

show abstract

“…In addition, some bacteria, including Actinomyces , Agathobacter , Bilophila , Klebsiella , Lachnospiraceae _ NK4A136 , Ruminococcaceae - UCG - 002 , and Ruminococcaceae _ UCG - 005 , were sensitive to TNFi treatment in AS nonsmokers, while Bacteroides , Faecalibacterium , Lachnoclostridium , Parabacteroides , Blautia , Butyricicoccus , and Escherichia - Shigella were not. This suggests that these bacteria were tolerant to TNFi treatment ( 109 ). Since TNFi do not work for all patients, one challenge to clinicians is to investigate the biomarker that can predict the clinical response to TNFi.…”

Section: Biological Disease-modifying Anti-rheumatic Drugsmentioning

confidence: 99%

Gut Microbiota–Medication Interaction in Rheumatic Diseases

Zhang

Chu

2021

Front. Immunol.

View full text Add to dashboard Cite

Besides its contribution to the development of rheumatic diseases, the gut microbiota interact with anti-rheumatic drugs. The intestinal microbiota can directly metabolize many drugs and indirectly change drug metabolism through a complex multi-dimensional interaction with the host, thus affecting individual response to drug therapy and adverse effects. The focus of the current review is to address recent advances and important progress in our understanding of how the gut microbiota interact with anti-rheumatic drugs and provide perspectives on promoting precision treatment, drug discovery, and better therapy for rheumatic diseases.

show abstract

Dynamic changes in gut microbiota under the influence of smoking and TNF-α-blocker in patients with ankylosing spondylitis

Cited by 22 publications

References 43 publications

Multi ‘Omics Analysis of Intestinal Tissue in Ankylosing Spondylitis Identifies Alterations in the Tryptophan Metabolism Pathway

Multi ‘Omics Analysis of Intestinal Tissue in Ankylosing Spondylitis Identifies Alterations in the Tryptophan Metabolism Pathway

Environmental Tobacco Smoke Exposure and Breastfeeding Duration Influence the Composition and Dynamics of Gut Microbiota in Young Children Aged 0–2 Years

Gut Microbiota–Medication Interaction in Rheumatic Diseases

Contact Info

Product

Resources

About